Immunogen Inc (IMGN) 2.80 $IMGN ImmunoGen Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Immunogen Inc (IMGN) 2.80 $IMGN

ImmunoGen Announces Departure of Chief Development Officer
BusinessWire - Tue Aug 09, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Charles Morris, MBChB, MRCP, Executive Vice President and Chief Development Officer, is leaving the Company effective September 2 to pursue an opportunity closer to his primary residence in Pennsylvania.
IMGN: 2.80 (-0.01)

ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:49PM CDT
ImmunoGen (IMGN) reported a wider-than-expected loss of 51 cents per share in the fourth-quarter of fiscal 2016.
GERN: 2.73 (+0.04), IMGN: 2.80 (-0.01), CORT: 5.35 (+0.02), ANIK: 47.94 (+0.70)

ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
BusinessWire - Fri Aug 05, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 2.80 (-0.01)

ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly Business Update
BusinessWire - Thu Aug 04, 5:30AM CDT
--Following positive meeting with FDA, Phase 3 FORWARD I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end.
IMGN: 2.80 (-0.01)

Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:30PM CDT
ImmunoGen (IMGN), which is set to report its fourth-quarter fiscal 2016 results on Aug 4, had recorded a negative surprise of 23.33% last quarter.
BMRN: 95.19 (+1.30), IMGN: 2.80 (-0.01)

Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
GlobeNewswire - Wed Jul 27, 3:30PM CDT
Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its board of directors, effective immediately. Mr. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics, a position he held since January 2009.
VTAE: 6.84 (-0.07), IMGN: 2.80 (-0.01)

ImmunoGen Announces Pricing of $100 Million Offering of 4.50% Convertible Senior Notes Due 2021
BusinessWire - Wed Jun 15, 7:58AM CDT
ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of $100 million aggregate principal amount of its 4.50% convertible senior notes due 2021 (the "Notes" in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act". ImmunoGen also granted the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $15 million aggregate principal amount of the Notes on the same terms and conditions to cover any overallotments.
IMGN: 2.80 (-0.01)

Why is ImmunoGen (IMGN) Stock Down Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 11:11AM CDT
On Tuesday, shares of ImmunoGen Inc. (IMGN) are falling, down over 14% in morning trading after the company proposed a $100 million convertible senior note offering due in 2021.
IMGN: 2.80 (-0.01)

ImmunoGen Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2021
BusinessWire - Mon Jun 13, 3:01PM CDT
ImmunoGen, Inc. (NASDAQ: IMGN) today announced its intention to offer and sell to the initial purchasers, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2021 (the "Notes" in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act". The sale is expected to close on June 20, 2016. ImmunoGen also intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $15 million aggregate principal amount of the Notes on the same terms and conditions to cover over-allotments, if any.
IMGN: 2.80 (-0.01)

Immunogen Shares Down 26.7% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Fri Jun 10, 1:27AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 1 month, Immunogen has returned 26.73% as of today's recent price of $5.07.
IMGN: 2.80 (-0.01)

ImmunoGen Announces Phase I Cohort Ovarian Cancer Data
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:57AM CDT
ImmunoGen (IMGN) reported efficacy and safety phase I cohort data evaluating mirvetuximab soravtansine as a single-agent therapy for ovarian cancer.
ANIP: 61.42 (+1.68), IMGN: 2.80 (-0.01), RTRX: 16.35 (+0.33), BMY: 56.76 (-0.63)

ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRa-Positive Ovarian Cancer
BusinessWire - Wed May 18, 4:01PM CDT
--Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016.
IMGN: 2.80 (-0.01)

Shares of IMGN Down 19.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 18, 1:30PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 3 weeks, Immunogen has returned 19.08% as of today's recent price of $5.60.
IMGN: 2.80 (-0.01)

ImmunoGen (IMGN) Posts Wider-than-Expected Q3 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:51AM CDT
ImmunoGen (IMGN) reports a loss of 37 cents per share wider than the Zacks Consensus Estimate of a loss of 30 cents.
GILD: 77.42 (-0.96), IMGN: 2.80 (-0.01), AEGR: 1.59 (-0.04)

Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 29, 2:33PM CDT
What: ImmunoGen reported its fiscal third-quarter earnings on Friday, and fell as much as 22%, but it wasn't the biotech's revenue or loss that has investors hitting the sell button. So what: For the record, ImmunoGen reported revenue of $19.7...
IMGN: 2.80 (-0.01)

Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 6.19 (unch), BIIB: 306.03 (+0.40), JNJ: 119.08 (-0.26), BMRN: 95.19 (+1.30), SHPG: 188.50 (+1.32), IMGN: 2.80 (-0.01), BXLT: 46.02 (-0.18), KERX: 4.13 (+0.03), NVS: 78.27 (-0.50)

What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.07 (-0.02), IMGN: 2.80 (-0.01), SNY: 38.41 (-0.06)

ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer
BusinessWire - Tue Apr 26, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16, 2016. Mr. Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.
IMGN: 2.80 (-0.01)

ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results
BusinessWire - Mon Apr 11, 10:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 29, 2016, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2016. Management also will provide an update on mirvetuximab soravtansine and other ImmunoGen product programs.
IMGN: 2.80 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 0

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 51

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 326

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 349

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 11

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 483

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 197

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Integer Holdings Opens Conversion on 2.125% Senior Notes

Updated Category News Views 151

Integer Holdings Announces Conversion of Senior Notes Integer Holdings Corporation (NYSE: ITGR) has recently made headlines with the announcement that its 2.125% Convertible Senior Notes, due in 2028, are now eligible for conversion. This pivotal move allows holders to convert their notes into either cash, common stock, or a combination of both. The option to convert is...

Continue Reading
Investors Urged to Consider Class Action Against Micron Technology

Updated Category News Views 119

Class Action Lawsuit Against Micron Technology, Inc. Levi & Korsinsky, LLP has alerted investors in Micron Technology, Inc. (NASDAQ: MU) regarding an ongoing class action securities lawsuit. This legal action aims to represent those investors who may have incurred financial losses during a specified period. Investors are encouraged to stay informed regarding this...

Continue Reading
Expansion Grant from Bradford White Boosts ECA Internship Program

Updated Category News Views 88

Bradford White Fuels Growth in ECA Internship Program Bradford White Corporation, known for its innovative water heating solutions, has committed $50,000 towards expanding the Energy Coordinating Agency's (ECA) internship program focused on heat pump technology. This initiative aims to enhance training opportunities for the next generation of plumbing and HVAC...

Continue Reading
Industrial Automation Market Set for Significant Growth Ahead

Updated Category News Views 199

Transformations in the Industrial Automation Market Landscape The industrial automation sector is undergoing a major shift as manufacturers worldwide increasingly adopt Industry 4.0 technologies and artificial intelligence. This evolution is spurred by pressing challenges including labor shortages and the need for enhanced operational efficiency. The market is projected...

Continue Reading
Exploring Competitive Landscape of Amazon.com in Retail Sector

Updated Category News Views 159

Understanding Amazon.com's Competitive Position In today's dynamic business world, understanding how companies perform against their competitors is essential. This article delves into a detailed examination of Amazon.com (NASDAQ: AMZN) and compares it with key rivals in the broadline retail sector. By exploring crucial financial data, market strategies, and growth...

Continue Reading